Aseptic Processing: A Primer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aseptic Processing: A Primer
PharmTech speaks to Ray O'Connor from the National Institute for Bioprocessing Research and Training (NIBRT) for an overview of aseptic processing.

Pharmaceutical Technology Europe


Equipment and cleanrooms

Q PTE: What type of equipment is typically used for aseptic processing?

O'Connor: The major piece of equipment, so to speak, is a cleanroom. Cleanrooms contain laminar airflow hoods, isolators or restricted access barrier systems (RABS), filling lines, sterilising filters, autoclaves for sterilising the equipment, depyrogenation tunnels for removing any endotoxins, as well as other equipment. Cleanrooms also have automated cleaning systems for reducing any low levels of contaminants prior to sterilising and isolators that have filling lines installed in them. These units are totally enclosed and have a localised area with what's called "Grade-A air" inside of them; this is where the filling line fills the product into final containers such as vials, syringes or bags.

A cleanroom could also have various environmental monitoring devices; filters, which are important for removing contaminants; and finally, single-use disposable systems, which are becoming more prevalent these days.

Q PTE: Can you provide more details about cleanrooms and the garments that are required?

O'Connor: There are a number of different standards around cleanrooms, but the International Organisation for Standardisation (ISO) 14644-1 defines a cleanroom as a room in which the concentration of airborne particles is controlled and which is constructed and used in a manner to minimise the introduction, generation and retention of particles inside the room and which other relevant parameters (e.g., temperature, humidity and pressure) are controlled as necessary.

Within the cleanroom, the critical components include high-efficiency particulate air filters on the ceilings that filter all the air coming into the room, as well as exhaust vents at the floor level. These vents ensure that laminar airflow and effective removal of air so that there are many air changes per hour, typically from 5 to 100. There should not be any drains inside an aseptic processing area in a cleanroom. Airlocks are important to facilitate the movement of people and equipment from one cleanroom into another.

It's important that cleanrooms are designed appropriately to ensure seamless and rounded floor-to-wall junctions to prevent buildup of any contamination or water. Floors and walls and ceilings must be constructed of smooth, hard surfaces that can be easily cleaned. One should limit the amount of fixtures and fittings on the walls to facilitate the ease of cleaning of walls, and layout of equipment must be optimised for the comfort, and movement of people.

In addition to ISO 14644, in Europe, cleanroom classifications are divided into Class A, B, C and D, where A is the most stringent and D is the least exacting. In the US, room classifications are referred to as Class 100, Class 1000, Class 10,000 and Class 100,000. The ISO standards then would be 5, 6, 7 and 8. The standards in general apply to particle sizes in the range of 0.5 microns to 5 microns.

The standards are used interchangeably, depending on where your site is located and where you're being regulated. So, if your site is regulated by FDA, it would use the Class 100, 10,000, 100,000 standards. Similarly, if your site follows the European standard, that means using Class A, B, C and D. A Class-A air area would be used to perform a high-risk operation such as filling or making aseptic connections. A Grade-B area is typically used for aseptic preparation and as a background environment for traditional filling operation. Grade C is used for preparation of solutions and equipment.

Microbial monitoring is also required to demonstrate the cleanliness of the cleanroom during production. The recommended limits are specific for the each room classification. Cleanrooms should have settle plates where air is allowed to settle to support the growth of bacteria. Staff can then see how much bacteria might be in the environment. Contact plates can be put up against walls and surfaces, and gloveprints can be used in Grade A and B areas. Gloveprints are where people actually place their gloved fingers to see whether there is any contamination present.

With each area, there are standardised limits. In a Grade-B room, for example, one can have no more than 10 colony forming units. It's important to trend these results, otherwise one cannot determine whether the room is under control. If there is no control, the product is at risk.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here